63 results on '"Barbaud A"'
Search Results
2. Nailfold capillaroscopy findings in cutaneous lupus erythematosus patients with or without digital lesions and comparison with dermatomyositis patients: A prospective study.
- Author
-
Monfort, Jean-Benoît, Chasset, François, Barbaud, Annick, Frances, Camille, and Senet, Patricia
- Subjects
DERMATOMYOSITIS ,LUPUS erythematosus ,CAPILLAROSCOPY ,LONGITUDINAL method - Abstract
Background: Differential diagnosis between cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) may be challenging if digital lesions occur. Objectives: To compare nailfold capillaroscopy (NFC) findings in CLE patients with or without digital involvement, and to compare capillaroscopic findings between CLE patients with digital lesions and DM patients. Methods: Prospective monocentric study including CLE and DM patients. NFC was performed and standardized items were recorded. Results: Fifty-one CLE patients and 10 DM patients with digital lesions were included. A scleroderma pattern was found in 6 patients (12%): in 5 out of 17 patients with digital lesions, compared with only 1 out of 34 patients without digital lesions (p = 0.01). In multivariate analysis, CLE digital lesions and digital ulcerations were statistically associated with scleroderma pattern. CLE digital lesions were significantly associated with architectural disorganization (p = 0.0003) and capillary rarefaction (p = 0.0038). A scleroderma pattern was significantly more frequent in DM patients (80%) than in CLE patients with digital lesions (30%, p = 0.018). Capillaroscopic findings were not significantly different between CLE patients with digital lesions and DM patients. Conclusion: Although scleroderma pattern is more frequent in DM patients than in CLE patients with digital lesions, NFC cannot formally distinguish CLE from DM. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Cutaneous Kikuchi disease-like inflammatory pattern without lymph node involvement is associated with systemic disease and severe features in lupus erythematous: A case-control study.
- Author
-
Lalevée, Sophie, Moguelet, Philippe, Hurabielle, Charlotte, Senet, Patricia, Pha, Micheline, Rivière, Sebastien, Barbaud, Annick, Amoura, Zahir, Francès, Camille, and Chasset, Francois
- Subjects
LYMPH nodes ,LUPUS nephritis ,CASE-control method ,SYSTEMIC lupus erythematosus ,SKIN biopsy - Abstract
Introduction: Kikuchi-Fujimoto disease (KFD) is a self-limited histiocytic necrotizing lymphadenitis sometimes affecting the skin. "Kikuchi disease-like inflammatory pattern" (KLIP) has been described in cutaneous lesions as similar pathological features in patients without lymph node involvement and as a potential clue for the diagnosis of lupus. We aimed to describe KLIP-associated clinical and immunological features in lupus patients with a retrospective case-control study. Methods: Thirteen cases of KLIP were included as well as thirty-nine age- and sex-matched control lupus patients without KLIP. At the time of KLIP diagnosis, 4/13 patients (31%) had isolated cutaneous lupus erythematosus (CLE) and 9/13 had (69%) systemic lupus erythematosus (SLE) including 6 (46%) with severe haematological, lung, cardiac or renal disease. KLIP features were observed in skin biopsies of different clinical presentations. Results: Compared with our control group, KLIP patients more frequently had SLE 9/13 (69%) versus 8/39 (21%) (OR 12.9; IC95% [2.86–58.2]; p = 0.0004) and more frequently severe SLE. Two out of four CLE exhibiting KLIP lesions (50%) developed severe SLE with cardiac or renal involvement after 12 and 24 months, respectively. Treatment with thalidomide 100 mg/day allowed rapid and complete clearance of cutaneous lesions in 6/6 KLIP patients. The need to use thalidomide tended to be more frequent in KLIP patients than in controls. Conclusion: Our study suggests that KLIP features in lupus skin lesions are associated with SLE and severe systemic features. Despite a limited number of isolated CLE patients with KLIP features in the skin, this observation may warrant closer follow-up on patients with a higher risk of developing SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Antituberculosis-Drugs Induced DRESS: A Multidrug Hypersensitivity or Drug Hypersensitivity Relapse? A Case Report.
- Author
-
Mansour, Khadija, Chadli, Zohra, Ben Fadhel, Najah, Ben Fredj, Nadia, Ben Romdhane, Haifa, Chaabane, Amel, Toumi, Adnene, and Aouam, Karim
- Subjects
DRUG therapy for tuberculosis ,ETHAMBUTOL ,LIVER function tests ,GAMMA-glutamyltransferase ,CETIRIZINE ,ADRENOCORTICAL hormones ,FEVER ,PYRAZINAMIDE ,DRESS syndrome ,EXANTHEMA ,ISONIAZID ,LYMPHATIC diseases ,EOSINOPHILIA ,LYMPHOCYTES ,DISEASE relapse ,ANTITUBERCULAR agents ,CUTANEOUS therapeutics ,RIFAMPIN ,BLOOD testing ,EDEMA ,ALANINE aminotransferase ,ASPARTATE aminotransferase - Abstract
DRESS related to first-line antituberculosis drugs (ATD) is a challenging diagnosis. With a long-lasting combined treatment of 4-concomitantly administrated drugs, identification of the culprit drug remains difficult and may expose patients to treatment interruption and affect their outcome. A 42-year-old female, treated with isoniazid, rifampicin, pyrazinamide and ethambutol for multifocal tuberculosis, developed, 40 days later, hyperthermia, facial edema, cervical lymphadenopathy and generalized exanthema. Biological test results revealed eosinophilia, atypical lymphocytes, and liver injury. DRESS was suspected, and ATD were withdrawn. As patch tests for the 4 ATD showed negative results, we decided to reintroduce pyrazinamide, ethambutol and rifampicin separately with a 3-day interval. Pyrazinamide and rifampicin were tolerated. However, after receiving ethambutol, she developed fever and generalized rash, with no biological abnormalities. Since ethambutol was claimed to be the culprit drug, isoniazid was added, and 10 hours later, the patient developed fever, facial edema, generalized rash, eosinophilia and liver injury. This clinical and biological pattern resolved 2 weeks later. This report suggests a hypersensitivity relapse to ethambutol after isoniazid-induced DRESS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Leukocytoclastic Vasculitis Following COVID-19 Vaccination: A Case Report.
- Author
-
Sebastian, Juny, Mathew, Merrin, Sharsty, Veeranna, and Ramesh, Madhan
- Subjects
PHYSICAL diagnosis ,IMMUNIZATION ,BIOPSY ,COVID-19 vaccines ,NEUTROPHILS ,ITCHING ,SEIZURES (Medicine) ,DRUG side effects ,VASCULITIS - Abstract
Background: Hypersensitivity or Leukocytoclastic vasculitis (LCV) following the COVID-19 vaccination has been reported rarely all over the world. LCV can be induced by certain factors such as infections, autoimmune disorders, malignancy, or some classes of drugs. Case presentation: A 32-year-old man, who was a known case of seizure disorder from his childhood presented to the department of dermatology with itchy red lesions on extremities and abdomen for the past 1 month. He explains a history of COVID-19 vaccination 1-month back and experienced itching on his lower limbs on the same day at night. A gradual worsening of the condition was observed day by day. He was hospitalized and diagnosed as LCV through clinical and laboratory findings. Conclusion: This case highlights a temporal association with the event of vaccination. The causality assessment showed an indeterminate causal association to LCV with COVID-19 Vaccination. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Implications of a Diabetic Foot Xerosis Treatment With an Emulsion Containing the Plant-Based Anionic Phospholipids.
- Author
-
Glonek, Thomas, Greiner, Jack V., Oliver, Paula J., and Baker, Terrance L.
- Subjects
SKIN diseases ,DRUG efficacy ,RESEARCH ,DIABETIC foot ,EMULSIONS ,RANDOMIZED controlled trials ,COMPARATIVE studies ,PRE-tests & post-tests ,DERMATOLOGIC agents ,BLIND experiment ,QUESTIONNAIRES ,PHOSPHOLIPIDS ,OINTMENTS ,CUTANEOUS therapeutics ,STATISTICAL sampling ,EVALUATION - Abstract
Purpose: This study compares and contrasts a skin cream containing plant-based anionic polar phospholipid (APP) technology with a mineral oil hydrocarbon (petrolatum)-based (MHB) skin cream technology in the treatment of skin xerosis (dryness) in diabetic feet. Skin cream with APP technology promotes phospholipid absorption, reparation of intercellular lamellae, and organization of water promoting hydration; whereas skin cream with mineral hydrocarbon-based (MHB) technology principally covers skin, preventing dehydration. Methods: Subjects (n = 54) with diagnoses of diabetes mellitus and foot skin dryness were studied using a multicenter, double-blind, masked-study design. An emulsion cream containing 0.05% APP in triglycerides (APP preparation) was compared to MHB skin cream, Eucerin
® (MHB preparation) applied topically to skin of the feet. Graded measurements were recorded on 4 efficacy variables including dryness, erythema, fissures, and itching and neurovascular assessments. Implications of the plant-based and mineral-based skin creams in the context of skin xerosis are contrasted. Results: APP and MHB preparations were similar in effectiveness and safety. There was no significant difference among any of the 4 efficacy variables (P <.5) including neurovascular measurements. The APP preparation is absorbed into the skin, whereas the MHB skin cream leaves detectable residues after each application. Conclusion: Although the APP and MHB preparations were not significantly different in effectiveness and safety, distinctively, application of the APP skin cream preparation absorbed into the skin leaving no discernible residue in contrast to the MHB preparation leaving residues potentiating textile damage. Both of these technologies function in the hydration of skin; however, they differ in their modes of action. The plant-based APP preparation functions actively by phospholipid and triglyceride absorption, reparation of skin lamellae, and in the consequent delivery and organization of waters of hydration in skin. The MHB preparation functions passively, hydrating the skin it covers by sealing the skin against dehydration. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
7. Evidence-based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications.
- Author
-
Cassinotti, Andrea, Batticciotto, Alberto, Parravicini, Marco, Lombardo, Maurizio, Radice, Paolo, Cortelezzi, Claudio Camillo, Segato, Simone, Zanzi, Federico, Cappelli, Antonella, and Segato, Sergio
- Subjects
CROHN'S disease ,INTESTINAL diseases ,METHOTREXATE ,CLINICAL trials ,OFF-label use (Drugs) ,BIOTHERAPY - Abstract
Introduction: Methotrexate (MTX) is included in the therapeutic armamentarium of Crohn's disease (CD), although its positioning is currently uncertain in an era in which many effective biological drugs are available. No systematic reviews or meta-analysis have stratified the clinical outcomes of MTX according to the specific clinical scenarios of its use. Methods: Medline, PubMed and Scopus were used to extract eligible studies, from database inception to May 2021. A total of 163 studies were included. A systematic review was performed by stratifying the outcomes of MTX according to formulation, clinical indication and criteria of efficacy. Results: The use of MTX is supported by randomized clinical trials only in steroid-dependent CD, with similar outcomes to thiopurines. The use of MTX in patients with steroid-refractoriness, failure of thiopurines or in combination with biologics is not supported by high levels of evidence. Combination therapy with biologics can optimize the immunogenic profile of the biological drug, but the impact on long-term clinical outcomes is described only in small series with anti-TNFα. Other off-label uses, such as fistulizing disease, mucosal healing, postoperative prevention and extraintestinal manifestations, are described in small uncontrolled series. The best performance in most indications was shown by parenteral MTX, favouring higher doses (25 mg/week) in the induction phase. Discussion: Evidence from high-quality studies in favour of MTX is scarce and limited to the steroid-dependent disease, in which other drugs are the leading players today. Many limitations on study design have been found, such as the prevalence of retrospective underpowered studies and the lack of stratification of outcomes according to specific types of patients and formulations of MTX. Conclusion: MTX is a valid option as steroid-sparing agent in steroid-dependent CD. Numerous other clinical scenarios require well-designed clinical studies in terms of patient profile, drug formulation and dosage, and criteria of efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. A case of successful acyclovir desensitization in a bone marrow transplant patient.
- Author
-
Andrade, Diana C, Fatakhova, Mariya, Fatteh, Shahnaz, and Rubio-Gomez, Heysu
- Subjects
STEM cell transplantation ,BONE marrow transplantation ,ACYCLOVIR ,ANGIONEUROTIC edema ,HERPES zoster ,DRUG allergy - Abstract
Introduction: The incidence of acyclovir-induced hypersensitivity is rare. To our knowledge, there are four published case reports of oral acyclovir desensitization in adults. Evidence-based guidelines prompt the use of acyclovir for herpes simplex virus (HSV) prophylaxis and treatment. Literature on the cross-reactivity of structurally similar antiviral agents is conflicting, presenting a clinical challenge when choosing an alternative agent. This is a case of successful acyclovir desensitization in an allogeneic stem cell transplant patient. Case Report: A 69-year-old female patient, diagnosed with myelodysplastic/myeloproliferative neoplasm, presented to the hospital for donor mismatch allogeneic bone marrow transplant. The patient reported acyclovir-induced angioedema while receiving treatment for non-complicated herpes zoster (shingles) infection. Management & Outcome: After the acyclovir oral desensitization was conducted in an ICU setting with 1:1 patient-nurse ratio, the patient was successfully started on acyclovir therapy, 800mg by mouth twice daily for HSV prophylaxis with no further complications. Discussion: Oral acyclovir desensitization can provide an option for HSV therapy in patients reporting severe allergy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels.
- Author
-
Yuki, Emily Figueiredo Neves, Soares, Renata, Kupa, Léonard de Vinci Kanda, Heise, Carlos Otto, Aikawa, Nadia Emi, Arnone, Marcelo, Romiti, Ricardo, Pedrosa, Tatiana do Nascimento, Silva, Clovis Artur Almeida da, Bonfa, Eloisa, and Pasoto, Sandra Gofinet
- Subjects
LUPUS erythematosus ,NEURAL conduction ,THALIDOMIDE ,PHARMACODYNAMICS ,TANDEM mass spectrometry ,SYSTEMIC lupus erythematosus - Abstract
Background: Few prospective studies in cutaneous and systemic lupus erythematosus (CLE/SLE) assessed thalidomide-induced peripheral neuropathy (TiPN) incidence/reversibility, and most have not excluded confounding causes neither monitored thalidomide plasma levels. Objectives: To evaluate TiPN incidence/reversibility, coasting effect and its association with thalidomide plasma levels in CLE/SLE. Methods: One-year prospective study of thalidomide in 20 CLE/SLE patients without pregnancy potential, with normal nerve conduction study (NCS), and excluded other PN causes. Thalidomide levels were determined by high-performance liquid chromatography/tandem mass spectrometry. Results: Twelve patients (60%) developed TiPN: 33.3% were symptomatic and 66.6% asymptomatic. Half of this latter group developed coasting effect (TiPN symptoms 1-3 months after drug withdrawal). The main predictive factors for TiPN were treatment duration ≥6 months (p = 0.025) and cumulative dose (p = 0.023). No difference in plasma thalidomide levels between patients with/without TiPN was observed (p = 0.464). After drug withdrawal, 75% symptomatic TiPN patients improved their symptoms. Seven TiPN patients underwent an additional NCS after drug withdrawal: 42.8% worsened NCS, 14.2% was stable, and 42.8% had improved NCS. Conclusion: Our data provides novel evidence of coasting effect in half of asymptomatic patients with TiPN. The irreversible nature of this lesion in 25% of TiPN patients reinforces the relevance of early NCS monitoring, and suggests thalidomide use solely as a bridge for other effective therapy for refractory cutaneous lupus patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Therapeutic Effectiveness of AxioBionics Wearable Therapy Pain Management System in Patients with Chronic Lower Back Pain.
- Author
-
Muccio, Philip, Schueller, Josh, van Emde Boas, Miriam, Howe, Norm, Dabrowski, Edward, and Durrant, David
- Abstract
Chronic lower back pain is one of the most common medical conditions leading to a significant decrease in quality of life. This study retrospectively analyzed whether the AxioBionics Wearable Therapy Pain Management (WTPM) System, a customized and wearable electrical stimulation device, alleviated chronic lower back pain, and improved muscular function. This study assessed self-reported pain levels using the visual analog scale before and during the use of the AxioBionics WTPM System when performing normal activities such as sitting, standing, and walking (n = 69). Results showed that both at-rest and activity-related pain were significantly reduced during treatment with the AxioBionics WTPM System (% reduction in pain: 64% and 60%, respectively; P <.05). Thus, this study suggests that the AxioBionics WTPM System is efficacious in treating chronic lower back pain even when other therapies have failed to sufficiently decrease reported pain levels. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Anaphylaxis to intravenous paracetamol containing povidone. A case report and narrative review of excipient allergy related to anaesthesia.
- Author
-
Preuss, James F, Goddard, Catherine E, Clarke, Russell C, Platt, Peter R, and Sadleir, Paul HM
- Subjects
ANAPHYLAXIS ,DRUG delivery systems ,SKIN tests ,ACETAMINOPHEN ,POVIDONE - Abstract
Investigation of intraoperative anaphylaxis includes the exclusion of potential trigger agents the individual was exposed to within a plausible interval preceding the reaction. Occasionally, none of these agents will test positive. In this situation it is important to consider that excipients may be responsible for anaphylaxis, that the dilutions prepared to test the medication may not contain an appropriate concentration of the excipient to induce a positive skin reaction, or if an alternative formulation of the medication is tested, it may not contain the culprit excipient. This case describes a patient, who previously experienced an anaphylactic reaction to Betadine® (Sanofi-Aventis Australia Pty Ltd, North Ryde BC, NSW) experiencing anaphylaxis in the recovery period after general anaesthesia where Betadine was avoided. The recently administered therapeutics were excluded by skin testing, however further investigation determined that a povidone-containing formulation of paracetamol had been administered. Skin testing with povidone-containing paracetamol resulted in a positive reaction in the patient, but not in a volunteer control. Pharmaceutical excipients are added to medications to increase absorption, shelf-life and efficacy. Different brands of the same drug may contain different excipients. When testing for anaphylaxis with such compounds one must be sure the dilution is appropriate for both the parent compound and the excipient to ensure the accuracy of skin-prick and intradermal testing. This case demonstrates the potential for excipients to cause severe allergy and the importance of detailed history pertaining to previous allergic episodes as even the most unlikely of medications can potentially result in anaphylaxis due to excipients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Multidisciplinary care in Stevens-Johnson syndrome.
- Author
-
Shanbhag, Swapna S., Chodosh, James, Fathy, Cherie, Goverman, Jeremy, Mitchell, Caroline, and Saeed, Hajirah N.
- Published
- 2020
- Full Text
- View/download PDF
13. HLA-B*1502 is associated with aromatic anticonvulsant drug-induced cutaneous adverse drug reactions among the Hakka population in China.
- Author
-
Zhiyuan Zheng, Hua Zhong, Qunji Zhang, Qingyan Huang, and Heming Wu
- Published
- 2020
- Full Text
- View/download PDF
14. Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption.
- Author
-
Takamasu, E, Yokogawa, N, Shimada, K, and Sugii, S
- Subjects
SYSTEMIC lupus erythematosus ,HYDROXYCHLOROQUINE ,DRUG side effects ,ALLERGIES ,SYSTEMIC lupus erythematosus treatment ,RETROSPECTIVE studies ,MULTIVARIATE analysis - Abstract
Objective: This study aimed to investigate the risk factors of hydroxychloroquine (HCQ)-induced hypersensitivity in patients with systemic lupus erythematosus (SLE) and to propose a simple dose-escalation regimen in cases of mild HCQ-induced hypersensitivity. Methods: We identified patients with SLE who started HCQ between 2009 and 2018 and cases of HCQ-induced hypersensitivity by reviewing the electronic medical charts. A simple dose-escalation regimen, starting at 40 mg/day with weekly increments of 40 mg/day to 200 mg/day, was used in patients with HCQ-induced hypersensitivity who did not require hospitalization or systemic steroid therapy. We then compared the clinical parameters of patients with and without HCQ-induced hypersensitivity and evaluated the success of our dose-escalation regimen. Results: We enrolled 302 patients with SLE and identified 25 cases of HCQ-induced eruption (8.3%). The mean Naranjo score of these patients was 5.1 ± 1.4 (min 3, max 8), and all 25 patients received a 'possible' (9) or 'probable' (16) score. A mild, generalized, maculopapular rash occurred in 24 patients, and urticaria occurred in one patient at 24 days (interquartile range 15–40 days) after the start of treatment. The proportion of cyclophosphamide use, glucocorticoid consisting of prednisolone 20 mg/day or more, and initiation of SMX-TMP within 28 days were higher in patients with skin eruptions. On multivariate analysis, only cyclophosphamide use was identified as a risk factor of HCQ-induced hypersensitivity (odds ratio = 12.3 (95% confidential interval 1.4–14.3)). Thirteen of the 14 patients on the dose-escalation regimen (92.9%) tolerated continued HCQ treatment. One patient re-experienced eruptions on day 10 day after starting HCQ. Conclusions: Mild late reactions are common in HCQ-induced hypersensitivity. A simpler dose-escalation regimen enables safe and easier reintroduction of HCQ but should not be applied to patients with immediate reactions or moderate late reactions. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. Hexamidine and Hexamidine Diisethionate.
- Author
-
Cherian, Priya, Bergfeld, Wilma F., Belsito, Donald V., Cohen, David E., Klaassen, Curtis D., Liebler, Daniel C., Rettie, Allan E., Ross, David, Slaga, Thomas J., Snyder, Paul W., Tilton, Susan, Fiume, Monice, and Heldreth, Bart
- Subjects
COSMETICS ,SAFETY - Abstract
The Expert Panel for Cosmetic Ingredient Safety reviewed newly available studies since their original assessment in 2007, along with updated information regarding product types and concentrations of use, and confirmed that Hexamidine and Hexamidine Diisethionate are safe as cosmetic ingredients in the practices of use and concentration as described in this report if used at concentrations less than or equal to.10%. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Lincomycin-Induced Acute Generalized Exanthematous Pustulosis Confirmed by Delayed Reading of Intradermal Testing.
- Author
-
Salem C, Ben, Fathallah, Neila, Slim, Raoudha, Ziadi, Sonia, and Ghariani, Najet
- Published
- 2016
- Full Text
- View/download PDF
17. Lack of association between lysyl oxidase-like 1 polymorphism in pseudoexfoliation syndrome and pseudoexfoliation glaucoma in North Indian population.
- Author
-
Pandav, Surinder Singh, Chakma, Partha, Khera, Alka, Chugh, Neera, Gupta, Parul Chawla, Thattaruthody, Faisal, Seth, Natasha Gautam, Raj, Srishti, Kaushik, Sushmita, Khullar, Madhu, and Ram, Jagat
- Published
- 2019
- Full Text
- View/download PDF
18. The Treatment of Low Leg Nonischemic Ulcers With a Traditional Chinese-Pharmaceutical Medium: A Randomized Controlled Multicenter Clinical Study.
- Author
-
Zhang, Jun, Chen, Xu, Yu, Linxiang, Xue, Jingxian, Zhu, Zhiyuan, Wang, Cong, Tang, Tian, Feng, Zeyu, and Yao, Chang
- Abstract
The aim of this study was to observe the curative effect and mechanism of Shengji Yuhong ointment in the healing of chronic ulcer of lower limbs. 400 patients were equally divided into treatment group and control group. The treatment group was covered with a piece of Shengji Yuhong ointment gauze, while the control group was covered with a piece of Vaseline gauze. Both groups changed dressings every other day for 4 weeks. On the 3rd, 7th, 14th, 21st, and 28th days of treatment, the reduction rate of wound area and the growth of wound granulation were observed and the levels of hydroxyproline and hemoglobin in wound granulation tissue were measured. The total effective rate was 99.00% in the treatment group and 71.00% in the control group. The treatment group was significantly better than the control group (P <.01). The ulcer area reduction rate of the treatment group was significantly higher than that of the control group (P <.01). The scores of ulcer depth, granulation color, and coverage area on the 7th, 14th, 21st, and 28th days after treatment in the treatment group were significantly lower than those before treatment (P <.05). After treatment, the levels of hydroxyproline and hemoglobin in granulation tissue of wounds in both groups were significantly higher than those before treatment (P <.01), and the levels in the treatment group were significantly higher than those in the control group (P <.01). Shengji Yuhong ointment can improve the healing rate of chronic ulcer of lower limbs. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. Gynecomastia in a Patient Taking Meloxicam—A Case Report.
- Author
-
Rosas, Steven L., Deyo-Svendsen, Mark E., Oldfather, Rachel Z., Phillips, Michael R., Israel, T. Andrew, and Weisenbeck, Emily R.
- Published
- 2020
- Full Text
- View/download PDF
20. Linear lupus panniculitis of the scalp with good response to thalidomide.
- Author
-
Navarro-Triviño, F J and Ortego Centeno, N
- Subjects
THALIDOMIDE ,SCALP ,ALOPECIA areata ,LUPUS erythematosus ,BLOOD cell count - Abstract
Alopecia is a frequent occurrence in lupus erythematosus (LE), that appears in more than half of the patients at some point during the course of the disease.[1] Probably, the paradigm of alopecia in lupus is focused on cutaneous discoid LE. CDLE is considered the most common primary acquired lymphocytic scarring alopecia in patients with LE. The most relevant difference between both types of LE is that LP is considered a non-scarring alopecia mainly when the inflammation is purely subcutaneous and that does not affect the dermis, therefore, with the possibility of hair regrowth. [Extracted from the article]
- Published
- 2019
- Full Text
- View/download PDF
21. A case of an acute cutaneous drug reaction with hydroxychloroquine.
- Author
-
Randhawa, Amritakaur and Wylie, Grant
- Published
- 2018
- Full Text
- View/download PDF
22. Author Index.
- Subjects
AUTHORS - Published
- 2017
- Full Text
- View/download PDF
23. Australian and New Zealand Anaesthetic Allergy Group Perioperative Anaphylaxis Investigation Guidelines.
- Author
-
Scolaro, R. J., Crilly, H. M., Maycock, E. J., McAleer, P. T., Nicholls, K. A., Rose, M. A., The, R. I. H., and The, Rih
- Subjects
ANAPHYLAXIS ,PERIOPERATIVE care ,DRUG allergy ,CHLORHEXIDINE ,BETA lactam antibiotics ,NEUROMUSCULAR blocking agents ,SKIN tests - Abstract
These guidelines are a consensus document developed by a working party of the Australian and New Zealand Anaesthetic Allergy Group (ANZAAG) to provide an approach to the investigation of perioperative anaphylaxis. They focus primarily on the use of skin testing as it is the investigation with the greatest clinical utility for the identification of the likely causative agent and potentially safer alternatives. The practicalities and process of skin testing, its limitations, and the place of other tests are discussed. These guidelines also address the roles of graded challenge and in vitro testing. The implications of anaphylaxis associated with neuromuscular blocking agents, beta-lactam antibiotics, local anaesthetic agents and chlorhexidine are discussed. Evidence for the recommendations is derived from literature searches using the words skin test, allergy, anaphylaxis, anaesthesia, and each of the individual agents listed in these guidelines. The individual articles were then reviewed for suitability for inclusion in these guidelines. Where evidence was not strong, as is the situation for many perioperative agents, expert consensus from the ANZAAG working party was used. These guidelines are intended for use by specialists involved in the investigation of perioperative allergy. They have been approved following peer review by members of ANZAAG and are available on the ANZAAG website: http://www.anzaag.com/anaphylaxis-management/testing-guidelines.pdf. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
24. Trigger factors of cutaneous lupus erythematosus: a review of current literature.
- Author
-
Szczęch, J., Samotij, D., Werth, V. P., and Reich, A.
- Subjects
LUPUS erythematosus ,SMOKING ,DISEASE exacerbation ,DISEASE susceptibility ,RADIOTHERAPY - Abstract
It is currently believed that autoimmune conditions are triggered and aggravated by a variety of environmental factors such as cigarette smoking, infections, ultraviolet light or chemicals, as well as certain medications and vaccines in genetically susceptible individuals. Recent scientific data have suggested a relevant role of these factors not only in systemic lupus erythematosus, but also in cutaneous lupus erythematosus (CLE). A variety of environmental factors have been proposed as initiators and exacerbators of this disease. In this review we focused on those with the most convincing evidence, emphasizing the role of drugs in CLE. Using a combined search strategy of the MEDLINE and CINAHL databases the following trigger factors and/or exacerbators of CLE have been identified and described: drugs, smoking, neoplasms, ultraviolet radiation and radiotherapy. In order to give a practical insight we emphasized the role of drugs from various groups and classes in CLE. We also aimed to present a short clinical profile of patients with lesions induced by various drug classes. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
25. Wound dressings, does it matter and why?
- Author
-
Maessen-Visch, Marjolein Birgitte and van Montfrans, Catherine
- Subjects
CLOTHING & dress ,LEG ulcers ,MICROBIOLOGY ,WOUND care ,COMPRESSION therapy ,COMPRESSION bandages - Abstract
Compression therapy and treating venous insufficiency is the standard of care for venous leg ulcers. The need for debridement on healing venous leg ulcers is still debated. Dressings are often used under compression bandages to promote faster healing and prevent adherence of the bandage to the ulcer. A wide range of dressings is available, including modern dressings with different kinds of biological activity. Microbial burden is believed to underlie delayed healing, but the exact role of microbiofilm in wound healing is uncertain. Before choosing a specific wound dressing, four main functions should be considered: (1) cleaning, (2) absorbing, (3) regulating or (4) the necessity of adding medication. There is no clear evidence to support the use of one dressing over another, as demonstrated by many Cochrane review studies. In addition, the prescriber should enquire about contact allergies that may also develop during wound treatment. It is shown that early intervention and early investment may reduce the cost of treatment. The choice of wound dressings should be guided by cost, ease of application and patient and physician preference and be part of the complete strategy. The role of the medical specialist is evident. Wound dressings matter as part of the optimal treatment in VLU patients. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
26. Erythematous Annular Plaques on a 9-Year-Old's Arms and Chest.
- Author
-
Kranseler, Julie and Gupta, Deepti
- Subjects
ARM ,ERYTHEMA ,EXANTHEMA ,ITCHING ,LIPS ,MUPIROCIN ,OINTMENTS ,PHYSICAL diagnosis ,CHEST (Anatomy) ,HYPERPIGMENTATION ,CLOTRIMAZOLE - Abstract
The article presents a case study of a 9-year-old girl presented to the clinic with pruritic rash with pustules. Topics discussed include the diagnosis of tinea corporis with majocchi's granuloma in the patient, the hyperpigmentation in patient's rashes, and the use of clotrimazole cream and mupirocin ointment for initial treatment. Also mentioned is the use of griseofulvin for treatment.
- Published
- 2018
- Full Text
- View/download PDF
27. Capillaroscopic findings in systemic lupus erythematosus with cutaneous digital lesions.
- Author
-
Lambova, Sevdalina
- Subjects
LUPUS erythematosus ,SYSTEMIC lupus erythematosus ,DERMATOMYOSITIS ,SYMPTOMS ,PULMONARY function tests ,RAYNAUD'S disease ,CONNECTIVE tissue diseases - Abstract
Nailfold capillaroscopy findings in cutaneous lupus erythematosus patients with or without digital lesions and comparison with dermatomyositis patients: a prospective study. Sir, The question about capillaroscopic findings in cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) with digital cutaneous lesions is insufficiently studied. In an own research, an "early" phase "scleroderma-like" pattern was observed in SLE patients, but in no case with DM. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
28. A case series using famciclovir in stem cell transplant recipients with valacyclovir hypersensitivity reactions.
- Author
-
Shah, Shreya A., Gulbis, Alison, and Wilhelm, Kaci
- Subjects
ACYCLOVIR ,ANTIVIRAL agents ,DRUG allergy ,DRUG side effects ,HEMATOPOIETIC stem cell transplantation ,HERPES simplex ,HERPES zoster ,PRODRUGS ,SURGICAL complications ,TREATMENT effectiveness - Abstract
Background: Herpes simplex virus and varicella zoster virus reactivation can occur in up to 32% and 40% of patients, respectively in the first year post-transplant without prophylaxis. Antiviral therapy consisting of acyclovir or valacyclovir is recommended for at least 1 year post stem cell transplant per evidence-based guidelines. Objective: In the event of a contraindication or hypersensitivity reaction to either drug, an alternative is essential based on the proven efficacy in reducing clinically significant herpes simplex virus and varicella zoster virus reactivations. We report two cases of successful initiation of famciclovir in stem cell transplant recipients experiencing hypersensitivity to valacyclovir or acyclovir. Discussion: In both cases, there were no hypersensitivity reactions or breakthrough viral infections after famciclovir initiation but this observation is limited by a small patient population. Conclusion: Due to the limited data available, famciclovir appears to be a reasonable option in immunocompromised patients with a mild valacyclovir or acyclovir hypersensitivity reaction. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
29. Acute Generalized Exanthematous Pustulosis Induced by Hydroxychloroquine: First Case Report in Canada and Review of the Literature.
- Author
-
Bailey, Kristy, Mckee, Daniel, Wismer, Judy, and Shear, Neil
- Abstract
Copyright of Journal of Cutaneous Medicine & Surgery is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2013
- Full Text
- View/download PDF
30. Differential diagnosis of leg ulcers.
- Author
-
Pannier, F. and Rabe, E.
- Subjects
ARTERIAL occlusions ,VASCULAR diseases ,DIFFERENTIAL diagnosis ,LEG ulcers ,SKIN tumors ,VASCULITIS ,DIABETIC foot ,DIAGNOSIS - Abstract
Leg and foot ulcers are symptoms of very different diseases. The aim of this paper is to demonstrate the differential diagnosis of leg ulcers. The majority of leg ulcers occur in the lower leg or foot. In non-venous ulcers the localization in the foot area is more frequent. The most frequent underlying disease is chronic venous disease. In 354 leg ulcers, Koerber found 75.25% venous leg ulcers, 3.66% arterial leg ulcers, 14.66% ulcers of mixed venous and arterial origin and 13.5% vasculitic ulcers. In the Swedish population of Skaraborg, Nelzen found a venous origin in 54% of the ulcer patients. Each leg ulcer needs a clinical and anamnestic evaluation. Duplex ultrasound is the basic diagnostic tool to exclude vascular anomalies especially chronic venous and arterial occlusive disease. Skin biopsies help to find a correct diagnosis in unclear or non-healing cases. In conclusion, chronic venous disease is the most frequent cause of leg ulcerations. Because 25% of the population have varicose veins or other chronic venous disease the coincidence of pathological venous findings and ulceration is very frequent even in non-venous ulcerations. Leg ulcers without the symptoms of chronic venous disease should be considered as non-venous. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
31. Drug-induced subacute cutaneous lupus erythematosus.
- Author
-
Callen, J. P.
- Subjects
LUPUS erythematosus ,IDIOSYNCRATIC drug reactions ,PHOTOSENSITIVITY disorders ,SKIN diseases ,CUTANEOUS manifestations of general diseases ,SKIN inflammation - Abstract
Subacute cutaneous lupus erythematosus (SCLE) is a subset of cutaneous lupus erythematosus with unique immunologic and clinical features. The first description dates back to 1985 when a series of five patients were found to have hydrochlorothiazide-induced SCLE. Since that time, at least 40 other drugs have been implicated in the induction of SCLE. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
32. Are Excipients Really Inert Ingredients? A Review of Adverse Reactions to Excipients in Oral Dermatologic Medications in Canada.
- Author
-
Noiles, Kristin and Vender, Ronald
- Abstract
Copyright of Journal of Cutaneous Medicine & Surgery is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2010
- Full Text
- View/download PDF
33. Nail Toxicity Induced by Cancer Chemotherapy.
- Author
-
Gilbar, Peter, Hain, Alice, and Peereboom, Veta-Marie
- Subjects
LITERATURE reviews ,DRUG therapy ,CANCER chemotherapy ,NAILS (Anatomy) ,ANTINEOPLASTIC agents ,DATABASES ,ANTHRACYCLINES ,PACLITAXEL ,PARONYCHIA ,COLD therapy - Abstract
Purpose. To provide a comprehensive literature review of chemotherapy-induced nail toxicity, including clinical presentation, implicated drugs and approaches for prevention and management. Data sources. A search of MEDLINE and EMBASE (1966-2008) databases was conducted using the terms (and variations of the terms) antineoplastic agents, nails, nail toxicity, onycholysis, and paronychia. Bibliographies from selected articles were reviewed for appropriate references. Data extraction. The retrieved literature was reviewed to include all articles relevant to the clinical presentation, diagnosis, incidence, prevention, and treatment of chemotherapy-induced nail toxicity. Data synthesis. Nail toxicity is a relatively uncommon adverse effect linked to a number of chemotherapeutic agents. Clinical presentation varies, depending on which nail structure is affected and the severity of the insult. Nail changes may involve all or some nails. Toxicity may be asymptomatic and limited to cosmetic concerns, however, more severe effects, involving pain and discomfort can occur. Taxanes and anthracyclines are the antineoplastic drug groups most commonly implicated. It is suggested that the administration schedule may influence the incidence of nail abnormalities, for example reported cases linked to the weekly administration of paclitaxel. Before instituting chemotherapy, patients should be educated regarding potential nail toxicities and strategies for prevention implemented. Management includes appropriate nail cutting, avoiding potential irritants, topical, or oral antimicrobials, and possibly cessation or dose reduction of the offending agent. Cryotherapy, through the application of frozen gloves or socks, has been beneficial in reducing docetaxel-induced nail toxicity and may be effective for other drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
34. Annual Review of Cosmetic Ingredient Safety Assessments: 2005/20061.
- Published
- 2008
- Full Text
- View/download PDF
35. Congenital Cerebellar Malignant Rhabdoid Tumor in an Infant with Junctional Epidermolysis Bullosa.
- Author
-
Krous, Henry F., Chadwick, Amy E., Haas, Elisabeth A., Breisch, Eric, and Masoumi, Homeyra
- Published
- 2007
- Full Text
- View/download PDF
36. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
- Author
-
Gürcan HM and Ahmed AR
- Published
- 2007
- Full Text
- View/download PDF
37. Frequency of Adverse Events Associated with Intravenous Immunoglobulin Therapy in Patients with Pemphigus or Pemphigoid.
- Published
- 2007
- Full Text
- View/download PDF
38. Final Report on the Safety Assessment of Ricinus Communis (Castor) Seed Oil, Hydrogenated Castor Oil, Glyceryl Ricinoleate, Glyceryl Ricinoleate SE, Ricinoleic Acid, Potassium Ricinoleate, Sodium Ricinoleate, Zinc Ricinoleate, Cetyl Ricinoleate, Ethyl Ricinoleate, Glycol Ricinoleate, Isopropyl Ricinoleate, Methyl Ricinoleate, and Octyldodecyl Ricinoleate1
- Abstract
The oil derived from the seed of the Ricinus communis plant and its primary constituent, Ricinoleic Acid, along with certain of its salts and esters function primarily as skin-conditioning agents, emulsion stabilizers, and surfactants in cosmetics, although other functions are described. Ricinus Communis (Castor) Seed Oil is the naming convention for castor oil used in cosmetics. It is produced by cold pressing the seeds and subsequent clarification of the oil by heat. Castor oil does not contain ricin because ricin does not partition into the oil. Castor oil and Glyceryl Ricinoleate absorb ultraviolet (UV) light, with a maximum absorbance at 270 nm. Castor oil and Hydrogenated Castor Oil reportedly were used in 769 and 202 cosmetic products, respectively, in 2002; fewer uses were reported for the other ingredients in this group. The highest reported use concentration (81%) for castor oil is associated with lipstick. Castor oil is classified by Food and Drug Administration (FDA) as generally recognized as safe and effective for use as a stimulant laxative. The Joint Food and Agriculture Organization (FAO)/World Health Organization (WHO) Expert Committee on Food Additives established an acceptable daily castor oil intake (for man) of 0 to 0.7 mg/kg body weight. Castor oil is hydrolyzed in the small intestine by pancreatic enzymes, leading to the release of glycerol and Ricinoleic Acid, although 3,6-epoxyoctanedioic acid, 3,6-epoxydecanedioic acid, and 3,6-epoxydodecanedioic acid also appear to be metabolites. Castor oil and Ricinoleic Acid can enhance the transdermal penetration of other chemicals. Although chemically similar to prostaglandin E1, Ricinoleic Acid did not have the same physiological properties. These ingredients are not acute toxicants, and a National Toxicology Program (NTP) subchronic oral toxicity study using castor oil at concentrations up to 10% in the diet of rats was not toxic. Other subchronic studies of castor oil produced similar findings. Undiluted castor oil produced minimal ocular toxicity in one study, but none in another. Undiluted castor oil was severely irritating to rabbit skin in one study, only slightly irritating in another, mildly irritating to guinea pig and rat skin, but not irritating to miniature swine skin. Ricinoleic Acid was nonirritating in mice and in one rabbit study, but produced welldefined erythema at abraded and intact skin sites in another rabbit study. Zinc Ricinoleate was not a sensitizer in guinea pigs. Neither castor oil nor Sodium Ricinoleate was genotoxic in bacterial or mammalian test systems. Ricinoleic Acid produced no neoplasms or hyperplasia in one mouse study and was not a tumor promoter in another mouse study, but did produce epidermal hyperplasia. Castor oil extract had a strong suppressive effect on S180 body tumors and ARS ascites cancer in male Kunming mice. No dose-related reproductive toxicity was found in mice fed up to 10% castor oil for 13 weeks. Female rats injected intramuscularly with castor oil on the first day after estrus had suppressed ovarian folliculogenesis and anti-implantation and abortive effects. Castor oil used as a vehicle control in rats receiving subcutaneous injections had no effect on spermatogenesis. A methanol extract of Ricinus communis var. minor seeds (ether-soluble fraction) produced anti-implantation, anticonceptive, and estrogenic activity in rats and mice. Clinically, castor oil has been used to stimulate labor. Castor oil is not a significant skin irritant, sensitizer, or photosensitizer in human clinical tests, but patients with occupational dermatoses may have a positive reaction to castor oil or Ricinoleic Acid. The instillation of a castor oil solution into the eyes of nine patients resulted in mild and transient discomfort and minor epithelial changes. In another study involving 100 patients, the instillation of castor oil produced corneal epithelial cell death and continuity breaks in the epithelium. Because castor oil contains Ricinoleic Acid as the primary fatty acid group, the Cosmetic Ingredient Review (CIR) Expert Panel considered the safety test data on the oil broadly applicable to this entire group of cosmetic ingredients. The available data demonstrate few toxic effects. Although animal studies indicate no significant irritant or sensitization potential, positive reactions to Ricinoleic Acid in selected populations with identified dermatoses did suggest that sensitization reactions may be higher in that population. Overall, however, the clinical experience suggests that sensitization reactions are seen infrequently. In the absence of inhalation toxicity data on these ingredients, the Panel determined that these ingredients can be used safely in aerosolized cosmetic products because the particle sizes produced are not respirable. Overall, the CIR Expert Panel concluded that these cosmetic ingredients are safe in the practices of use and concentrations as described in this safety assessment. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
39. Final Report on the Safety Assessment of Hexamidine and Hexamidine Diisethionate1.
- Abstract
Hexamidine Diisethionate functions as a biocide in cosmetics at concentrations of 0.03% to 0.1% in 38 cosmetic products. Hexamidine functions as a biocide and preservative in cosmetics, but is not in current use in cosmetics, but it is used in over-the-counter (OTC) drug products. Hexamidine was poorly absorbed by human cadaver skin when in water-oil formulations or in a gel that simulated a cosmetic product formulation. Hexamidine Diisethionate was poorly absorbed by the skin of live rats and was not stored in any tissue type. Hexamidine Diisethionate given to rats intravenously was rapidly metabolized to Hexamidine. Excretion was primarily via the feces, with a small amount excreted in the urine. Acute oral LD50 values of Hexamidine Diisethionate were 0.71 to 2.5 g/kg in mice and 0.75 g/kg in rats. Dermal exposure to 4 g/kg Hexamidine Diisethionate in rats or up to 9.4 ml/kg of a 0.1% Hexamidine Diisethionate solution under occlusion in rabbits produced no mortality or other signs of toxicity. The no-observed-effect level (NOEL) for oral subchronic toxicity of Hexamidine Diisethionate in rats was 50 mg/kg/day. No signs of toxicity were observed with 2% Hexamidine Diisethionate in subchronic studies using rabbits. Application of 0.1 ml of 0.11% Hexamidine Diisethionate in aqueous solution to the eyes of rabbits produced transient reactions; 0.05% produced no reactions. Slight erythema was observed with 0.10% Hexamidine Diisethionate applied to the abraded skin of 1/11 albino rabbits. A 40% solution of Hexamidine Diisethionate applied to 10% of the body surface of rats produced slight erythema, slight edema, and scabbing in some animals at varying times after treatment. Hexamidine Diisethionate was not a sensitizer in the guinea pig maximization test or in an intracutaneous guinea pig sensitization test. Hexamidine Diisethionate was not a photosensitizer in albino rabbits. Hexamidine Diisethionate was not mutagenic in a bacterial reverse mutagenicity assay or clastogenic in mammalian cells. Hexamidine Diisethionate at 0.10% did not provoke primary irritation, inflammation, or sensitization in a clinical test of 200 human subjects. One case report of photosensitivity to Hexamidine and one of contact sensitivity to Hexamidine were reported. There were nine case reports of contact sensitivity to Hexamidine Diisethionate. A European safety assessment recommended a limit of 0.1% Hexamidine Diisethionate in leave-on and rinse-off cosmetic products. In considering the available data, the Cosmetic Ingredient Review (CIR) Expert Panel acknowledged the lack of carcinogenicity and reproductive/developmental toxicity data. Because genotoxicity studies were negative, and there were no structural alerts, the Panel concluded that it was unlikely that these ingredientswould be carcinogenic. Because the rate of absorption of Hexamidine and Hexamidine Diisethionate is slow, there is no tissue accumulation, and excretion is rapid and complete, and there was no toxicity in a subchronic study, the Panel concluded that dermal exposures would not likely present a risk of reproductive/ developmental toxicity. The Panel noted that a guinea pig maximization study using Hexamidine Diisethionate produced no dermal reactions and that a clinical test at 0.1% produced no irritation or sensitization. The Panel also expressed concern regarding the possible presence of 1,4-dioxane as an impurity, and stressed that the cosmetic industry should continue to use the necessary purification procedures to remove these impurities from the ingredient before blending into cosmetic formulations. The Panel noted that there are no data for concentration of use for eye makeup and baby products, and was concerned that there should not be unrestricted concentration levels in these product categories. Although there are gaps in knowledge about product use, the overall information available on the types of products in which these ingredients are used and at what concentration indicate a pattern of use. Within this overall pattern of use, the Expert Panel considers all ingredients in this group to be safe at concentrations up to and including 0.1%. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
40. Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders.
- Published
- 2007
- Full Text
- View/download PDF
41. Gender assignment to nouns codeswitched into French: Observations and explanations.
- Subjects
NOUNS ,FRENCH language ,LINGUISTICS ,PHONETICS - Abstract
This article investigates the assignment of grammatical gender to foreign nouns codeswitched into French, where gender assignment is required. Contrary to other studies, this study is based on a questionnaire of 75 words filled by both monolingual French speakers and native speakers of French bilingual in English. The results are analyzed in the light of criteria for gender assignment that are established both for borrowed words (from previous studies on borrowings in French as well as Spanish and German) and for native French words (from studies in French morphology). Comparisons between the groups show that there is little agreement between monolinguals and bilinguals as well as among monolinguals, showing that the meaning of a word is of primary importance in assigning grammatical gender. Results also show that the majority of words are assigned to the masculine gender. The analysis of factors influencing gender assignment reveals that bilingual participants rely on semantic criteria (biological sex and semantic analogy) and/or formal (morphological endings, phonetics, and orthographical factors) criteria to assign gender to the words in the questionnaire. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
42. Leg Ulcers of Unusual Causes.
- Author
-
Arun Chakrabarty and Tania Phillips
- Subjects
LEG ulcers ,THROMBOANGIITIS obliterans ,BLOOD diseases ,VASCULITIS ,SARCOIDOSIS ,CALCIPHYLAXIS - Abstract
In this review, unusual causes of leg ulcers are examined with an emphasis on pathophysiology, clinical presentation, and epidemiology. Cutaneous ulcers due to malignancy of unusual leg ulcers with hematologic disorders, vasculitis, sarcoidosis, calciphylaxis, Buerger's disease, and pyoderma gangrenosumare discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2003
43. Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus.
- Author
-
Piette, J-C, Sbaï, A, and Francès, C
- Subjects
SIDE effects of thalidomide ,LUPUS erythematosus treatment ,THROMBOSIS ,MULTIPLE myeloma - Abstract
Editorial. Focuses on thalidomide-associated thromboembolic events and its particular clinical relevance in patients affected by lupus. Early fetal thrombosis induced by thalidomide in mice; Deep-vein thrombosis in patients treated with thalidomide; Potential prothrombotic risk associated with thalidomide in multiple myeloma and connective tissue disorders.
- Published
- 2002
- Full Text
- View/download PDF
44. A Listing of Skin Conditions Exhibiting the Koebner and Pseudo-Koebner Phenomena with Eliciting Stimuli.
- Author
-
Rubin, Adam I. and Stiller, Matthew J.
- Published
- 2002
- Full Text
- View/download PDF
45. Remarks on Technology and Art.
- Author
-
Ellul, Jacques
- Subjects
ART & technology ,TECHNOLOGY & society ,ART & science - Abstract
Discusses how contemporary art relates to modern technology and the status of such an art in the technocratric system. Relationship between contemporary art and science; Ways in which technology has influenced artists; Separation of art and technology; How art has become a confirmation of the technocratic system.
- Published
- 2001
- Full Text
- View/download PDF
46. Language in Canada (Book review).
- Author
-
Fee, Margery
- Subjects
- LANGUAGE in Canada (Book)
- Abstract
Reviews the book `Language in Canada,' edited by John Edwards.
- Published
- 2000
- Full Text
- View/download PDF
47. Canada.
- Author
-
New, W.H. and Dahms, Moshie
- Published
- 1988
- Full Text
- View/download PDF
48. Sugammadex and hypersensitivity.
- Author
-
Baldo, B. A.
- Subjects
SUGAMMADEX ,ANAPHYLAXIS - Abstract
A review of the articles on sugammadex and anaphylaxis by L. Slavic and co-authors, J. Jeyadoss and co-authors, and PHM Sadleir and co-authors published in the January 2014 issue of Anaesthesia and Intensive Care journal is presented.
- Published
- 2014
49. Fixed drug eruption induced by topical olopatadine ophthalmic solution.
- Author
-
Bilgili, SG, Karadag, AS, Karadag, R, Bulut, G, and Calka, O
- Subjects
DRUG interactions ,OPHTHALMIC drugs ,HISTAMINE receptors ,MAST cells ,CONJUNCTIVITIS ,ANTIHISTAMINES - Abstract
Fixed drug eruption (FDE) usually develops after oral administration and is described as a cutaneous reaction recurring at the same location each time the drug is taken. Olopatadine is both a H1 histamine receptor antagonist and a mast cell stabilizer, indicated for the treatment of allergic conjunctivitis. Here, we report a 14-year-old male patient who developed FDE localised on the lateral side of periorbital rim bilaterally, whilst applying olopatadine 0.1% ophthalmic solution for the treatment of allergic conjunctivitis. As far as we know, FDE due to olopatadine has not been previously reported in the literature. We deem it appropriate to report this case because FDE that results from the application of topical drugs is a rare event in the literature. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
50. Basal Cell Carcinoma Is Not Granulation Tissue in the Venous Leg Ulcer.
- Author
-
Janković, Aleksandar, Binić, Ivana, and Ljubenović, Milanka
- Abstract
The authors present a case of a 76-year-old female with a 7-year history of a nonhealing leg ulcer. The wound surface had epithelial tissue present in a diffuse way with shiny granulations on parts of the edge of the ulcer. A biopsy of the ulcer edge was performed to study the reasons for the absence of response to treatment and the presence of abnormal granulation tissue. The result showed the presence of a basal cell carcinoma. The authors conclude that skin biopsy is very important in nonhealing chronic venous ulcers because carcinomas may mimic granulation tissue and complicate venous ulcers. [ABSTRACT FROM AUTHOR]
- Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.